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o r i g i n a l a r t i c l e
Epidemiological Model for Clostridium difficile
Transmission in Healthcare Settings
C. Lanzas, DVM, PhD;1,2 E. R. Dubberke, MD, MPH;3 Z. Lu, PhD;1 K. A. Reske, MPH;3 Y. T. Gro¨hn, DVM, PhD1
objective. Recent outbreaks of Clostridium difficile infection (CDI) have been difficult to control, and data indicate that the importance
of different sources of transmission may have changed. Our objectives were to evaluate the contributions of asymptomatic and symptomatic
C. difficile carriers to new colonizations and to determine the most important epidemiological factors influencing C. difficile transmission.
design, setting, and patients. Retrospective cohort study of all patients admitted to medical wards at a large tertiary care hospital
in the United States in the calendar year 2008.
methods. Data from six medical wards and published literature were used to develop a compartmental model of C. difficile transmission.
Patients could be in one of five transition states in the model: resistant to colonization (R), susceptible to colonization (S), asymptomatically
colonized without protection against CDI (C), asymptomatically colonized with protection against CDI (C), and diseased (ie, with CDI;
D).
results. The contributions of C, C, and D patients to new colonizations were similar. The simulated basic reproduction number
ranged from 0.55 to 1.99, with a median of 1.04. These values suggest that transmission within the ward alone from patients with CDI
cannot sustain new C. difficile colonizations and therefore that the admission of colonized patients plays an important role in sustaining
transmission in the ward. The epidemiological parameters that ranked as the most influential were the proportion of admitted C patients
and the transmission coefficient for asymptomatic carriers.
conclusion. Our study underscores the need to further evaluate the role of asymptomatically colonized patients in C. difficile transmission
in healthcare settings.
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Clostridium difficile is the leading cause of infectious diarrhea
in hospitals and has become, along with methicillin-resistant
Staphylococcus aureus, one of the most common causes of
health care–associated infections.1,2 The incidence and severity
of C. difficile infection (CDI) have increased dramatically
since 2000, and CDI is estimated to cause as many as 20,000
deaths and to cost as much as $3.2 billion per year in US
acute care facilities alone.3-5 CDI outbreaks have become more
common, and infection control–based CDI prevention efforts
appear to be less effective than in the past.2,6
Studies on C. difficile nosocomial transmission were un-
dertaken in the late 1980s.7-9 Clabots et al.9 provided evidence
that asymptomatically colonized patients newly admitted to
a ward were an important source of transmission. Patients
with symptomatic CDI, as compared to asymptomatic C. dif-
ficile carriers, were more likely to contaminate their sur-
roundings and the hands of healthcare workers with C. dif-
ficile.7,8 Therefore, it was concluded that symptomatic CDI
patients were the main source of C. difficile transmission. As
a result, current CDI prevention efforts, such as isolation and
contact precautions, target only symptomatic CDI patients.10
Changes in the epidemiology of C. difficile and health care
delivery since the original transmission studies were con-
ducted may have shifted the relative contribution of symp-
tomatic CDI patients and asymptomatic carriers.11 For ex-
ample, since 2002 alcohol-based hand hygiene products have
been recommended as the primary form of hand hygiene in
healthcare settings.12 C. difficile spores are resistant to the
bactericidal effects of alcohol.13 Use of alcohol-based hand
hygiene products by healthcare workers after they have cared
for asymptomatic C. difficile carriers may increase those car-
riers’ contribution to C. difficile transmission.13 Conversely,
rapid identification of patients with CDI and placing these
patients in contact precautions may have reduced the con-
tribution to C. difficile transmission from patients with
CDI.10,14
Mathematical models of disease transmission provide a
conceptual framework for understanding and quantifying
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figure 1. Flow diagram of the epidemiological model for Clostridium difficile transmission in a hospital ward. Five transition states are
included: resistant (R), susceptible (S), asymptomatically colonized without protection against C. difficile infection (C), asymptomatically
colonized with protection against C. difficile infection (C), and diseased (D).
transmission and intervention strategies. Mathematical mod-
els have helped researchers to understand the epidemiology
of other nosocomial pathogens, such as vancomycin-resistant
enterococcus15,16 and methicillin-resistant S. aureus.17 To date,
efforts to model C. difficile transmission have been limited;
Starr et al.18 modeled C. difficile transmission in a geriatric
ward. They quantified C. difficile transmission within and
between rooms but did not address the relative contributions
of asymptomatic and clinical patients as sources of new in-
fections.18 In addition, the data were collected prior to the
changes in CDI epidemiology.19
Our objectives were to provide a framework for evaluating
the relative contributions of asymptomatically and symptom-
atically colonized patients to new colonizations and to de-
termine the most important epidemiological factors influ-
encing C. difficile transmission at the ward level. For that
purpose, we developed an epidemiological model of C. difficile
and evaluated the impact of different epidemiological param-
eters on C. difficile transmission. We used recent data from
a large tertiary care hospital and published literature to es-
timate model parameters.
methods
Data
Data were collected retrospectively from six medicine wards
at Barnes-Jewish Hospital in St. Louis, Missouri, during the
calendar year 2008. The data were collected electronically
from the hospital’s medical informatics databases and in-
cluded patient demographics, dates of hospital and ward ad-
mission, discharge, and transfers, laboratory tests, and med-
ication exposures. Two of the wards had 26 beds each, 1 had
29 beds, and 3 had 30 beds each. On average, 153 patients
were admitted per ward per month, including 109 per month
whose length of stay was greater than 48 hours. The micro-
biology laboratory at Barnes Jewish Hospital tests only di-
arrheal stool for the presence of C. difficile toxin (Remel
ProSpecT C. difficile Toxin A/B). Testing stool for the presence
of C. difficile toxin requires a physician order. During the
study period, patients with a diagnosis of CDI were placed
into isolation, and contact precautions were initiated. Isola-
tion and precautions were typically initiated only after the
patient had received a diagnosis of CDI. The data set included
11,046 patients. The mean age of patients was 57 years old.
They had a mean Charlson Comorbidity Score of 1.8, and
54% were female. On average, there were 2.2 incident cases
of clinical CDI (patients who acquired CDI after admission)
per month in each ward (157 in total for all six wards) and
2.2 prevalent cases of clinical CDI (patients with CDI on
admission) per month on each ward.
Epidemiological Model
We developed an epidemiological model for C. difficile trans-
mission in a ward (Figure 1). In an epidemiological model,
the patient population is divided into transition states ac-
cording infection status. The C. difficile epidemiological
model included the following transition states: resistant to
colonization (R), susceptible to colonization (S), asymptom-
atically colonized without protection against CDI (C),
asymptomatically colonized with protection against CDI
(C), and diseased (ie, with CDI, D; Table 1). Resistant in-
dividuals were defined as patients who had not received an-
timicrobial treatment and had a normal intestinal microbiota
that provided “colonization resistance” against C. difficile.20
Although patients with normal flora can be colonized with
C. difficile, such colonizations appear to be transient, and a
normal flora is associated with a much lower risk of devel-
opment of CDI than is an altered flora.8,9,21 Hence, we as-
sumed that individuals with a normal intestinal microbiota
were resistant to C. difficile colonization. Susceptible patients
received antimicrobial treatment and could be colonized by
modeling clostridium difficile transmission 555
table 1. Summary of the Transition States Included in the Epidemiological Model for Clostridium
difficile Transmission Based on Four Criteria: Antimicrobial Treatment, Presence of Toxigenic C. difficile,
Immune Response, and Clinical Symptoms
Antimicrobial
treatment
Presence of
toxigenic C. difficile
Immune response
against C. difficile
C. difficile
symptoms
Resistant    
Susceptible    
Colonized without protection    
Colonized with protection    
Diseased   / 
C. difficile. Antibiotic treatment disrupts the normal micro-
biota, making patients significantly more susceptible to C.
difficile colonization and development of CDI after coloni-
zation.22 Three types of colonized patients were included in
the model: C, C, and D. We considered two types of asymp-
tomatically colonized patients, according to the risk of de-
veloping CDI. Colonized patients either could or could not
mount a protective response. Asymptomatically colonized pa-
tients who did not mount an immune response could develop
disease. Diseased patients were treated with antibiotics. De-
pending on treatment success, diseased patients could either
continue to be diseased or become susceptible again at the end
of therapy. Patients could be admitted and discharged in any
of the five states, and C patients were assumed to be colonized
during the entire duration of their hospitalization.7-9 The math-
ematical model is presented in the appendix.
Parameterization
Model parameters are described in Table 2. The proportions
of admitted patients defined as resistant (R) and diseased (D)
were obtained from the hospital data. Patients who did not
receive antibiotics during their admission were considered
resistant. Patients with a positive stool sample within 48 hours
after admission were considered to have been diseased when
admitted.10 The antibiotic prescription rate was obtained from
the hospital data set and was based on the admission rate
and the percentage of individuals who received antibiotics
during their stay. Patients were considered susceptible after
being exposed to antibiotics. The microflora returns to nor-
mal 1–49 days after the end of the treatment, depending on
the antimicrobial group.22 We set the restoration rate to 0.033/
day, which means that the microflora of each patient recovers
by 3.3% each day and therefore returns to normal after 30
days, on average. Vancomycin and metronidazole are con-
sidered the standard treatments for CDI. For 80% of patients
with CDI, diarrhea symptoms resolve within a typical 10-day
treatment, regardless of antibiotic type.24 Therefore, the treat-
ment rate was set to 0.10/day, the inverse of the treatment
duration, and the probability of successful treatment was set
to 0.80. The clinical disease rate is the inverse of the incu-
bation period.9,25 The mean fraction of colonized patients that
mounted an immune response was set at 0.60; 60% of the
patients that became colonized had detectable antibody re-
sponses.23 Discharge rates, the inverse of length of stay, were
obtained from the hospital data set. Patients without anti-
microbial treatment (R) during the hospitalization had the
shortest length of stay (3 days). Susceptible and colonized
patients had an average length of stay of 6.7 days. For clinical
CDI (ie, D patients), the length of stay was 14.7 days (Table
2). Default values for transmission coefficients and the pro-
portion of patients admitted in states S, C, and C were set
to match observed attack rates.
Simulations
The model predicted the following outcomes: the basic re-
production number (R0), the average number of secondary
colonizations generated by each type of admitted colonized
patient (C, C, D), and the number of CDI cases per 1,000
admitted patients. The basic reproduction number is the av-
erage number of secondary colonizations generated by a pri-
mary C. difficile colonization in a C. difficile–free ward. It
conveys information regarding the transmissibility of the
pathogen in a specific setting. The higher the R0, the greater
the pathogen transmissibility. To quantify R0 and the con-
tribution of the three types of admitted colonized patients to
new colonizations, we constructed the so-called next-gener-
ation matrix for the model.26 The next-generation matrix al-
lowed us to express outcomes as a function of the epide-
miological model parameters.26 Then we performed a
sensitivity analysis to assess which epidemiological parameters
were the most influential. The sensitivity analysis used the
Sobol’ sensitivity indices.27 Sobol’ indices are an ANOVA-like
decomposition, and they partition the variability of the model
output (ie, expected secondary colonizations and R0) into
main effects of the parameters and total effects (including
interactions between parameters). In addition, simulations of
the stochastic model (see “Stochastic Model” in the appendix
for details) were performed to evaluate the effect of varying
the proportions of admitted colonized and diseased patients
and other parameters on the number of CDI cases per 1,000
admitted patients.
results
Model simulations are presented in Figures 2–5. The R0
ranged from 0.55 to 1.99 (Figure 2). For almost 50% of the
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table 2. Parameters for the Clostridium difficile Model
Symbol Description, units
Baseline
value
Range used in
sensitivity analysis Source
ar Proportion of admitted patients that are resistant,
dimensionless 0.75 ... Hospital dataa
as Proportion of admitted patients that are susceptible,
dimensionless 0.22 0.15–0.29 Estimatedb
acn, acp Proportion of admitted patients that are colonized (C

and C, respectively), dimensionless 0.01 ... Estimatedb
ad Proportion of admitted patients with C. difficile infec-
tion (diseased), dimensionless 0.01 ... Hospital dataa
a Antibiotic prescription rate, per day 0.5 0.35–0.65 Hospital dataa
v Restoration rate of colonization resistance, per day 0.033 0.023–0.043 Rafii et al22
bc, bd Transmission coefficients for asymptomatic carriers
and diseased patients, respectively, per individual-
day 0.007 0.004–0.01 Estimatedb
f Fraction of colonized patients that mount immune
response, dimensionless 0.60 0.45–0.75 Kyne et al23
 Treatment rate, per day 0.10 0.07–0.13 McFarland24
p Probability of successful treatment, dimensionless 0.80 0.56–1 McFarland24
f Clinical disease rate, per day 0.2 0.14–0.26 Clabots et al;9 Chang et al25
kr Discharge rate for resistant patients, per day 0.33 0.23–0.43 Hospital data
a
k Discharge rate for susceptible and colonized patients,
per day 0.15 0.105–0.195 Hospital dataa
kd Discharge rate for diseased patients, per day 0.068 0.048–0.088 Hospital data
a
a Parameters obtained directly from the hospital data.
b Values set to match observed attack rate.
simulations, R0 was less than 1. This is a threshold value
because if R0 is greater than 1, on average 1 colonization leads
to more than 1 secondary colonization and therefore, the
number of colonizations will grow in the population. The
parameters that explained most of the variation in R0 were
the variation in transmission parameters (bc and bd) and the
duration of stay of the colonized patients (k and kd; Figure
2). Specifically, the two most influential parameters were the
transmission coefficient for asymptomatic patients (bc) and
the discharge rate for susceptible and colonized patients (k).
The proportion of the R0 variation that was not explained
directly by the parameters was very small (1%) and was due
to interactions among parameters (Figure 2).
Figure 3 displays the average number of new colonizations
that each type of colonized patient can produce once admitted
to a C. difficile–free ward. These values may not be attainable
because the wards are not completely occupied by susceptible
individuals and have a continuous inflow of newly admitted
patients and outflow of discharged patients. Nevertheless,
they provide a way to rank the contributions of different types
of admitted colonized individuals to new colonizations. The
three types of colonized patients contributed similarly to new
colonizations, each resulting in an average of 0.40 new C
colonizations and 0.60 new C colonizations (Figure 3). Ad-
mitted C patients contribute to new colonizations as C and
D (if they move into the D state). The parameters that ex-
plained most of the variation in the contribution of the three
types of colonized patients were the fraction of newly colo-
nized patients that mount an immune response (f ), the trans-
mission coefficient for diseased patients (bd), the transmission
coefficient for asymptomatic carriers (bc), and the discharge
rate of colonized and susceptible patients (k).
Figures 4 and 5 display the results of the stochastic sim-
ulations. The proportion of patients admitted as C was the
epidemiological parameter with the strongest influence on
the number of new CDI cases per 1,000 admitted patients.
For the scenario with the baseline parameters, the median
for the number of CDI cases was 17.85 per 1,000 patients
(Figure 4). Increasing the proportion of admitted C by 0.01
increases the median attack rate to 27.54 new cases per 1,000
patients. Changing the proportions of C and D patients had
similar effects, but their influence on the number of CDI
cases was lower than that of the proportion of C patients
(Figure 4). Among the other parameters evaluated, trans-
mission coefficients, clinical disease rate, and the fraction of
newly colonized patients that mount an immune response
were the most influential (Figure 5).
discussion
We present a mathematical model of the transmission of C.
difficile in healthcare settings. We considered three types of
colonization during hospitalization (Table 1). We omitted
other states and transitions that may be relevant at the com-
munity level. Proposed models for community-associated C.
difficile included states such as “clinically resolved–colonized”
modeling clostridium difficile transmission 557
figure 2. Distribution of the basic reproduction number when parameters are varied (A) and contribution of the grouped parameters
to the variation observed in the basic reproduction number (B). We grouped the parameters according to whether they determine (1)
patient susceptibility (as, a, v, kr), (2) transmission (bc, bd), (3) duration of stay of colonized individuals (k, kd), (4) treatment (, p), or
(5) virulence (f, f). Parameters are defined in Table 2.
figure 3. Number of new secondary colonizations (state C or
C) generated by each type of admitted colonized patient (C, C,
or D). See Figure 1 for definition of states C, C, and D.
(CDI successfully treated but patient remains colonized) and
transitions such as decolonization.28 At the hospital level, the
likelihood of observing some of these states and transitions
is low because of the short duration of patient stay. For ex-
ample, we assumed that the colonization lasted for the com-
plete duration of the hospitalization because follow-up studies
have indicated that patients remained colonized 30 days after
discharge.23
The increases in CDI incidence and severity and difficulties
in controlling CDI have led to the conclusion that the epi-
demiology of C. difficile has changed in recent years.11,29 Po-
tential explanations include alterations in healthcare practices
over the past 20 years, increased asymptomatic carriage, in-
creased patient susceptibility, and organism-specific factors
that have increased virulence or transmission.30 All these
changes may have increased transmission coefficients (eg, the
use of alcohol-based hand hygiene products over hand wash-
ing may have increased bc), increased the proportions of ad-
mitted asymptomatic carriers (acn and acp for C
 and C
patients, respectively) and diseased patients (ad), or decreased
the fraction of colonized patients capable of mounting an
immune response (f ), among other effects. We evaluated the
effect of modifying these epidemiological parameters in C.
difficile epidemiology. The admission of colonized patients,
especially C patients, highly influenced C. difficile outcomes.
The number of CDI cases increased as the percentage of
admitted colonized patients increased (Figure 3). In addition,
the basic reproduction number (R0) ranged from 0.55 to 1.99.
These values suggest that for a wide range of parameter values,
transmission within the ward alone cannot sustain C. difficile
colonization. Therefore, the admission of colonized patients
plays an important role in sustaining transmission in the
ward. An increase in the proportion of admitted patients who
are already colonized is possible, as data indicate that C.
difficile contamination of foodstuffs is more common than
previously recognized and that community-associated CDI is
increasing.31,32
The number of CDI cases was also sensitive to variations
in the incubation period. As the incubation period increased,
the number of cases due to transmission decreased because
the chances that an asymptomatic colonized patient left be-
fore becoming diseased increased. Therefore, increased in-
cubation periods may increase the number of patients with
community-onset, healthcare facility–associated CDI. These
patients may be readmitted later as diseased patients. Previous
research indicates that patients with health care–onset CDI
were more likely to receive a fourth-generation cephalospo-
rin or intravenous vancomycin than were patients with
community-onset healthcare facility–associated CDI.33 These
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figure 4. Effect of varying the proportions of admitted patients
colonized without immunity (acn; A), colonized with immunity (acp;
B), and with disease (ad; C) on the average number of Clostridium
difficile infection (CDI) cases per 1,000 admissions.
figure 5. Effect of varying the transmission coefficients (bc and
bd; A), the clinical disease rate (f; B), and the proportion of col-
onized patients who mount an immune response (f; C) on the
number of Clostridium difficile infection (CDI) cases per 1,000 ad-
missions. The dashed line represents the simulation with the baseline
parameter values.
antibiotics may shorten the incubation period because of their
broad impact on the normal microflora, or they may be mark-
ers for sicker patients more susceptible to C. difficile.22,34 Other
influential parameters were the transmission coefficients and
the fraction of patients that mounted an immune response
against C. difficile. These results are supported by studies
demonstrating that efforts to reduce transmission of C. dif-
ficile from hands of healthcare workers are highly effective35
and by data demonstrating the importance of the immune
response and the risk of developing CDI.10
Interestingly, epidemiological parameters linked to patient
susceptibility, such as antimicrobial treatment rate, had little
impact on C. difficile transmission (Figure 2). This appears
to be contrary to CDI prevention recommendations and data
indicating that antimicrobial stewardship is effective at pre-
venting CDI.23,36 There are several potential explanations for
this. In this study, we did not differentiate between classes of
antibiotics in terms of risk of CDI. This may have limited
our ability to detect a reduction in CDI incidence caused by
limiting antibiotic exposures. A large percentage of patients
were considered susceptible because of antimicrobial treat-
ment; therefore, the rate at which the resistant patients be-
come susceptible patients was not a limiting factor in C.
difficile transmission. Conversely, most data supporting an-
timicrobial stewardship to prevent CDI occur in outbreak
settings in conjunction with other prevention efforts. It is
possible that antimicrobial stewardship by itself is less effec-
tive in nonoutbreak situations or in the absence of efforts to
reduce C. difficile transmission.
There are some limitations to this study. Actual C. difficile
colonization prevalence on admission and at discharge from
the study wards was not available. However colonization
prevalence reported in the literature was used for the param-
eter estimates, and assessment of colonization status con-
ducted after the study period indicates that the levels of prev-
alence of C. difficile colonization on admission and discharge
at the study hospital are consistent with those in the literature
(5% and 15%, respectively; E. R. Dubberke, unpublished
data). The diagnosis of CDI was based on the result of a toxin
enzyme immunoassay in patients with diarrhea. Toxin en-
zyme immunoassays suffer from variable sensitivities, pos-
sibility missing true occurrences of CDI.36 This often results
in repeat testing and consequently increases the risk of having
a false positive result as well.37 Transmission coefficients were
identified as important parameters. Therefore, the different
routes of transmission through contaminated healthcare
workers and environment must be considered explicitly in
the model to design future interventions to prevent C. difficile
transmission.
The epidemiology of C. difficile has changed dramatically
in the past decade, with notable increases in CDI incidence
and severity. Current prevention recommendations appear to
be effective in combating CDI outbreaks; however, they may
be less effective at preventing endemic CDI.38 Our study un-
derscores the need to further evaluate the role of asymptom-
atically colonized patients in C. difficile transmission and to
identify methods to best prevent C. difficile transmission from
these patients. The integration of C. difficile–based transmis-
sion modeling with culture-based data available after changes
in CDI epidemiology and the development of methods to
rapidly and reliably identify asymptomatic C. difficile carriers
are necessary for a complete understanding of the most cost-
effective methods of preventing CDI, the most common
health care–associated infection.
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appendix
The deterministic differential equations for the model are as
follows (parameters are defined in Table 2):
dR
p a dN vS k R aR, (A1)r rdt
dS
p a dN aR pD vS kS lS, (A2)sdt
dC
 p a dN (1 f )lS fC  kC , (A3)cndt
dC
p a dN f lS kC , (A4)cpdt
dD
p a dN fC  pD k D, (A5)d ddt
 lp b (C  C ) b D, (A6)c d
 Np R S C  C  D. (A7)
At the disease-free equilibrium, the number of susceptible
patients (S0) can be described as a function of antibiotic pre-
scription (a), colonization resistance restoration (v), dis-
charge rates (k, kr), and number of ward beds (N) as
(a k  a)Ns rS p . (A8)0 [a a k  (1 a )k v]s r s
For the next-generation matrix, we define the matrices F
and V as
F(x)iFp ,[ ]x xpx 0j
V(x)iVp ,[ ]x xpx 0j
where Fi(x) is the number of new infections in the ith com-
partment from xj infectious individuals and Vi(x) is the net
change of individuals in the ith compartment by any other
means. The rates are evaluated at the disease-free equilibrium
. For the model, F and V are given asxp x 0
(1 f )b S (1 f )b S (1 f )b Sc 0 c 0 d 0 
Fp fb S fb S fb S ,c 0 c 0 d 0 
0 0 0 
k f 0 0 
Vp 0 k 0 , 
f 0p k d
1 0 0
k f
1
1V p 0 0 .
k
f 1 0
(p k )(f k) p k d d
The next-generation matrix, K, is FV1. The entry (i, j) of K
is the expected number of secondary infections in compart-
ment i produced by individuals initially in compartment j,
K K K    c c c c c d 
1Kp FV p K K K ,    c c c c c d 
0 0 0 
where
(1 f )b S (1 f )fb Sc 0 d 0K p  , (A9) c c
f k (p k )(f k)d
(1 f )b Sc 0K p , (A10) c c k
(1 f )b Sd 0K p , (A11)c d p kd
fb S ffb Sc 0 d 0K p  , (A12) c c
f k (p k )(f k)d
fb Sc 0K p , (A13) c c k
fb Sd 0K p . (A14)c d p kd
Each entry (i, j) in the K matrix represents the expected
number of secondary colonizations in compartment i pro-
duced by individuals initially in compartment j. The basic
reproduction number is the spectral radius of the matrix K,
(1 f )b S (1 f )fb S fb Sc 0 d 0 c 0R p r(K)p   .0
f k (p k )(f k) kd
(A15)
Stochastic Model
We developed an individual-based stochastic model based on
Figure 1. A combined algorithm based on the Gillespie direct
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table a1. Transition Probabilities and Discharge Events
Events Transition probability Duration Changes
Restoration colonization resistance vSDt o(Dt) R p 1, S p 1
Antibiotic treatment aRDt o(Dt) R p 1, S p 1
Treatment success pDDt o(Dt) S p 1, D p 1
Colonization without immune response (1  f )lSDt  o(Dt) S p 1, C p 1
Colonization with immune response flSDt  o(Dt) S p 1, C p 1
Disease fCDt o(Dt) C p 1, D p 1
State of patient upon discharge
R 1/kr R p 1
S 1/k S p 1
C 1/k C p 1
C 1/k C p 1
D 1/kd D p 1
and first-reaction methods was used to simulate our individ-
ual-based stochastic model.39 In our simulations, when pa-
tients were admitted to hospital or moved to a different state,
they were supposed to stay in a constant duration (depending
which state they were in) prior to discharge unless they moved
to another state. To utilize full beds in a ward, the admission
was assumed to be immediate once a patient was discharged.
Our model is a modified continuous-time Markov chain
model, where time is continuous, , and the statet  [0, )
space is discrete. The state space for the model is
 X(t)p (R(t), S(t), C (t), C (t), D(t)),
and . The probability of a transi-DX(t)p X(t Dt) X(t)
tion is
 P[DX(t)p (r, s, c , c , d)X(t)].
We assume that Dt is sufficiently small that the values of r,
s, c, c, and d are nonzero. There are 11 possible changes
in state where at least one of (r, s, c, c, d) is nonzero. The
transition probabilities for the possible changes between states
and the five types of discharge events are defined in Table
A1.
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